[Comment] Role of bisphosphonates in non-metastatic prostate cancer

Bone is the most common site for distant metastases in prostate cancer and accounts for most morbidity attributable to end-stage prostate cancer. Treatments targeted at bone—eg, zoledronic acid and denosumab—reduce the risk of complications in the setting of metastatic castration-resistant prostate cancer. report oncological endpoints of the Randomised Androgen Deprivation and Radiotherapy (RADAR) study, which aimed to address two important issues in the management of locally advanced prostate cancer: first, what duration of androgen suppression is best for patients treated with external-beam radiotherapy (EBRT) and second, does the addition of zoledronic acid improve cancer control? Their results answer some questions and raise others.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Comment Source Type: research